Insights

AI Discovery Octant combines AI, cell engineering, high throughput chemistry, and automation to discover small molecule drugs. This creates potential demand for tools that improve model development, experimental data management, workflow orchestration, and research productivity.

Clinical Expansion Octant describes itself as clinical stage and is advancing drug candidates for protein misfolding diseases, including inherited retinal disease. Its collaboration to expand the Uni Rare natural history study may create needs for clinical research operations, patient recruitment, data capture, and study analytics.

Funded Collaboration Octant has raised $115 million, including an $80 million Series B, and secured up to $30.5 million in ARPA H support for open source AI models addressing drug side effects. The funded initiative may provide a timely opening for partnerships in AI infrastructure, model validation, data security, and research collaboration.

Growing Organization With 51 to 200 employees and multiple research and development programs, Octant may be scaling both scientific and operational capabilities. Its use of platforms such as Apache Spark, Airflow, Slack, Google Workspace, and recruiting systems suggests opportunities in integration, workflow automation, talent acquisition, and secure collaboration.

Leadership Access CEO Sri Kosuri and cofounder and president Ramsey Homsany have participated in major healthcare and ophthalmology conferences, signaling active engagement with investors and industry partners. Business development teams can use these forums and Octant’s disease focused collaborations to build executive level relationships and explore partnership needs.

Similar companies to Octant

Octant Tech Stack

Octant uses 8 technology products and services including iCIMS, Apache Spark, Apache Airflow, and more. Explore Octant's tech stack below.

Media & News

Octant's Email Address Formats

Octant uses at least 4 email formats:
Octant Email FormatsExamplePercentage
First@octant.bioJohn@octant.bio
78%
FLast@octant.bioJDoe@octant.bio
8%
Last@octant.bioDoe@octant.bio
9%
First.Last@octant.bioJohn.Doe@octant.bio
5%

Frequently Asked Questions

What is Octant's official website and social media links?

Minus sign iconPlus sign icon
Octant's official website is octant.bio and has social profiles on LinkedIn and Crunchbase.

How much revenue does Octant generate?

Minus sign iconPlus sign icon
As of October 2026, Octant's annual revenue is estimated to be $25M - $50M.

What is Octant's SIC code and NAICS code?

Minus sign iconPlus sign icon
Octant's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Octant have currently?

Minus sign iconPlus sign icon
As of October 2026, Octant has approximately 68 employees across 3 continents, including North America, Europe and Asia. Key team members include Vp Of Platform: L. N. H., Head Of Compute: J. P. and Head Of Discovery Biology And Project Team Leader: E. J. Explore Octant's employee directory with LeadIQ.

What industry does Octant belong to?

Minus sign iconPlus sign icon
Octant operates in the Biotechnology Research industry.

What technology does Octant use?

Minus sign iconPlus sign icon
Octant's tech stack includes iCIMS, Apache Spark, Apache Airflow, Google Workspace, OpenAI, Webflow, Greenhouse and Slack.

What is Octant's email format?

Minus sign iconPlus sign icon
Octant's email format typically follows the pattern of First@octant.bio. Find more Octant email formats with LeadIQ.

How much funding has Octant raised to date?

Minus sign iconPlus sign icon
As of October 2026, Octant has raised $115M in funding. The last funding round occurred on May 21, 2022 for $80M.

When was Octant founded?

Minus sign iconPlus sign icon
Octant was founded in 2017.
Octant logo

Octant

Biotechnology ResearchCalifornia, United States51-200 Employees

Octant is a biotechnology research company based in Emeryville, California, focused on developing small-molecule therapies for diseases driven by protein misfolding. It pursues a pipeline across rare diseases, oncology, and immunology, aiming to advance drug candidates by integrating biology and chemistry. The firm emphasizes an automated, scalable approach to drug discovery that aims to accelerate research by coordinating biological and chemical insights.

In 2026, Octant announced a collaboration with the Foundation Fighting Blindness to expand a natural history study for inherited retinal diseases caused by mutations in the RHO gene. It operates in the biotechnology research sector and maintains a mid-sized team.

Section iconCompany Overview

Website
octant.bio
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $115M

    Octant has raised a total of $115M of funding over 3 rounds. Their latest funding round was raised on May 21, 2022 in the amount of $80M as a Series B.

  • $25M - $50M

    Octant's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.